Table 8.
Use of GLM/SRF to determine feature importance for different components of the critical features determined in Table S3.
| Predisposing Factors |
Post-Vaccination Side Effects | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tiredness | Fever | Headache | Injection Site Pain and Swelling | Myalgia | Sleepiness and Laziness | ||||||||
| GLM | RF | GLM | RF | GLM | RF | GLM | RF | GLM | RF | GLM | RF | ||
| Number of doses | Two | 9.93 | 0.6 | - | - | 7.1 | 0.93 | - | - | 3.72 | 0.91 | - | - |
| Gender | Female | 40.69 | 1.97 | - | - | - | - | 34.92 | 1.16 | 2.82 | 0.73 | - | - |
| Experiencing COVID-19 vaccine hesitancy and related fears before vaccination | Yes | 28.05 | 1.19 | - | - | 4.84 | 1.05 | 18.65 | 0.76 | 3.08 | 0.94 | 0.69 | 1.59 |
| Type of COVID-19 vaccine | AstraZeneca | 34.72 | 1.57 | 23.76 | 1.51 | 19.45 | 1.71 | 19.67 | 1.53 | 4.58 | 1.7 | 0.18 | 0.59 |
| Pfizer-BioNTech | −14.82 | 0.47 | −0.17 | 1.15 | 4.3 | 0.74 | 0.1 | 0.81 | −1.31 | 0.53 | 0.19 | 0.85 | |
| Sinopharm | −22.12 | 0.38 | −0.1 | 0.87 | −6.71 | 1.4 | −54.27 | 1.86 | −10.67 | 1.32 | −0.4 | 1.55 | |
| Moderna | 28.78 | 0.87 | 23.7 | 1.23 | 11.09 | 0.78 | 19.85 | 1.00 | 2.34 | 0.89 | 0.46 | 1.06 | |
| Sputnik V | −3.82 | 0.17 | −0.1 | 0.52 | −6.46 | 1.05 | −17.1 | 0.49 | 0.06 | 0.26 | −0.35 | 1.16 | |
| SinoVac | −28.84 | 0.62 | −0.1 | 0.35 | −6.16 | 0.91 | −54.07 | 1.48 | −8.76 | 0.74 | −0.37 | 0.87 | |
| Age (years) | <20 | - | - | - | - | - | - | - | - | −3.91 | 0.64 | - | - |
| 20–39 | - | - | - | - | - | - | - | - | −1.09 | 0.92 | - | - | |
| 40–59 | - | - | - | - | - | - | - | - | −4.55 | 0.44 | - | - | |
| >60 | - | - | - | - | - | - | - | - | −11.29 | 0.92 | - | - | |
GB is used as AutoML. GLM, generalized linear models; RF, random forest.